Podcasts about covalent

What is COF 999?UC Berkeley chemistry professor Dr. Omar Yaghi recently led a study which has the potential to be revolutionary in reducing the quantity of carbon dioxide present in the atmosphere. “Covalent organic framework number 999,” or COF 999, is a yellow, powder-like material that has billions of tiny holes. Inside of these holes, researchers in Dr. Yaghi's lab have installed molecular units that can seek out carbon dioxide, enabling the substance to suck in and capture the carbon dioxide. COF 999 has a huge capacity for absorbing emissions; half a pound of the powder can absorb as much carbon dioxide as a tree captures in a year.The carbon dioxide problemThe quantity of carbon dioxide in the atmosphere has reached an all-time high, with a global average in 2023 of 419.3 parts per million. This immense amount of carbon dioxide in the atmosphere comes from a number of human sources, the most common of which is the burning of fossil fuels such as coal, oil, and natural gas for energy. Carbon dioxide is the most abundant greenhouse gas in the atmosphere, and contributes significantly to global warming and other environmental issues, including ocean acidification.Applying COF 999 In an interview with Forbes, Dr. Yaghi described the way he sees COF 999 being implemented as a solution. The powder can be made into pellets or a coating, and then integrated into facilities where flue gas –the gas that is released from industrial processes –is released. “This flue gas would pass through the material and because it just plucks out CO2, it cleans CO2 from that flue before it reaches the atmosphere.” According to the San Francisco Standard, Dr. Yaghi says that the powder “requires no energy, shows no signs of degradation even after 100 uses, and is made from inexpensive, commercially available materials.”  Another benefit is that the material only needs to be heated to 50 or 60 degrees Celsius, rather than to 120 like many other traditional materials necessary for carbon capture.In order to see significant change in the atmosphere's carbon dioxide concentration, we will need to couple preventing carbon dioxide emissions with direct air capture, which COF 999 can also do. According to Zihui Zhou, a UC Berkeley graduate student who worked in Dr. Yaghi's lab says, “Currently, the CO2 concentration in the atmosphere is more than 420 ppm, but that will increase to maybe 500 or 550 before we fully develop and employ flue gas capture. So if we want to decrease the concentration and go back to maybe 400 or 300 ppm, we have to use direct air capture.” It will take time, however, for scientists to be able to use COF 999 effectively. This is because the powder has not been tested in real-life scenarios, and therefore the costs and risks from the powder are largely unknown; for example, the powder might restrict air flow through filters when applied, reducing the practicality of the powder.  About our guestDr. Omar Yaghi is a professor of chemistry at the University of California Berkeley, and the Founding Director of the Berkeley Global Science Institute, whose mission is to build centers of research in developing countries and provide opportunities for young scholars to discover and learn. He is an elected member of the U.S. National Academy of Sciences as well as the German National Academy of Sciences Leopoldina. ResourcesClimate.gov: Climate Change: Atmospheric Carbon DioxideForbes: This Powder Could Be A Gamechanger For Capturing CO2The San Francisco Standard: The new solution to climate change? A yellow powder you can hold in your fingersUC Berkeley News: Capturing carbon from the air just got easierSmithsonian Magazine: This New, Yellow Powder Quickly Pulls Carbon Dioxide From the Air, and Researchers Say ‘There's Nothing Like It'For a transcript, please visit https://climatebreak.org/cof-999-carbon-capture-with-dr-omar-yaghi/

Dr Michael Lange and Dr Susan Summerton discuss how new science is proving a low carb diet may not be as healthy as we once thought. Ketogenic diets and carnivore diets that stimulate the body to burn fat for fuel instead of glucose may cause accelerated cellular aging. The doctors discuss how important healthy carbohydrates from the correct source are for overall health. They also both agree that for weight loss it is much better to watch calories than carbohydrates. Dr Lange mentions the development of a new advanced meal replacement called Fortifeye Fit Meal that is in the development phases now. Fortifeye Fit Meal will be a combination of egg white protein, fiber, vitamins, minerals, fruits and vegetables, probiotics, prebiotics and enzymes along with organic mushrooms and a fat metabolizer complex. This new FIt MEal is in the developmental phases now and will be available before the summer of 20025. Dr Lange discusses the powers of a super fruit called Pomegranate. He states that some specific polyphenols in pomegranate stimulate the production of urolithin a in the gut. Urolithin a has some amazing anti-aging and wellness benefits. Fortifeye will use a powerful pomegranate extract in the new Fit Meal to gain these valuable benefits. Dr Lange and Dr Summerton reveal the science behind grass fed non denatured whey protein and glutathione. Covalent bonded cystine in whey is one of the best ways to stimulate glutathione and stimulate muscle growth and strength. They continue the 30% off the Fortifeye Vegan Super Protein for one more week. They go over some nutritional pearls and hacks that tell you what fruits and vegetable not to mix and which ones not to eat unless organically grown. They also discuss a new drug delivery system for chronic eye allergies called Dextenza that they now offer at the Lange Eye Institute Both doctors discuss important steps to alleviate dry eye naturally and then discuss amniotic membranes for dry eye. This was the first show of the New Year. Happy New Year!Support the show: https://www.drmichaellange.com/category/ask-the-doctor/See omnystudio.com/listener for privacy information.

Ganesh Swami is a co-founder of Covalent – the leading modular on-chain data infrastructure network. He has been leading the Covalent Network to build the most robust organization, improving data accessibility and empowering blockchain innovation since 2019. With a background in building protein simulation algorithms to solve cancer, Ganesh is a serial entrepreneur and has over a decade of experience in big data analytics. Ganesh's LinkedIn: https://www.linkedin.com/in/ganswami/ Ganesh's X: https://x.com/gane5hCovalent Website: https://www.covalenthq.com/ Covalent X: https://x.com/Covalent_HQ --- Support this podcast: https://podcasters.spotify.com/pod/show/crypto-hipster-podcast/support

In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. Our Guest:Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.comThis episode was funded by Eli Lilly, Canada. 

We've been of the opinion that the Cosmos Hub and Ethereum rollup-centric roadmap are converging. Both of the scaling methodologies are somewhat opposites (appchains at first vs. baselayer L1 then building vertically), however they seem to be converging. The convergence of roadmaps is particularly interesting because of the challenges faced by Cosmos Zones and the need for upgrades via forking the chain. In today's episode, Andy hosted Ganesh Swamy, founder of Covalent, to discuss this convergence and more. We talked about scaling data availability in rollups with Celestia and blobs, preserving and accessing transaction data with the Ethereum wayback machine and competition between data availability solutions and Ethereum itself. Covalent emerged from a simple idea of 'pulling Ethereum transactions into Excel'. The core idea of creating a persistent, perpetual storage machine for blockchains is a result of Ganesh's extensive database engineering experience. We also discussed how this works under the hood, and why having a long-term data storage solution for blockchains is crucial. Towards the end we went on to discuss the troubles of the token economy that we are currently in. Negative sentiment, early stage investing, high FDV low float, and some of the potential solutions that we see out there. Join us for a holistic overview of some of the topics shaping the modular ecosystem going forward. Website: https://therollup.co/ Spotify: https://open.spotify.com/show/1P6ZeYd.. Podcast: https://therollup.co/category/podcast Follow us on X: https://www.x.com/therollupco Follow Rob on X: https://www.x.com/robbie_rollup Follow Andy on X: https://www.x.com/ayyyeandy Join our TG group: https://t.me/+8ARkR_YZixE5YjBh The Rollup Disclosures: https://therollup.co/the-rollup-discl

The ETH wayback machine stores onchain data of most major EVM blockchains in order to let you query it and put it into a spreadsheet to analyze or do your taxes with.

CME credits: 1.00 Valid until: 04-06-2025 Claim your CME credit at https://reachmd.com/programs/cme/applexus-hot-topics-2024-clinical-updates-on-non-covalent-btk-inhibitors-in-cll-and-mcl/26980/ On-demand webcast of expert faculty presentation and case discussion on treating patients with CLL and MCL with non-covalent BTK inhibitors, as presented at CCO and PCE's APPlexus Hot Topics 2024.=

CME credits: 0.50 Valid until: 14-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-changing-covalent-btk-inhibitor-treatment-in-a-patient-intolerant-to-ibrutinib-or-acalabrutinib/24454/ Selection of Bruton's tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.

Featuring perspectives from Dr Lindsey Roeker and Dr Jeff Sharman, including the following topics: An Audio Depiction of Mechanisms of Action of Bcl-2 Inhibitors, Anti-CD20 Antibodies and Covalent and Noncovalent Bruton Tyrosine Kinase Inhibitors; Mechanisms of Resistance (0:00) Current Management Approaches for Patients with Chronic Lymphocytic Leukemia (CLL) — Dr Sharman (12:27) Future Directions in the Care of Patients with CLL — Dr Roeker (33:54) CME information and select publications  

Founder and CEO, Sanjay Garodia, introduces OMAS - the full lifecycle product for primary Debt Capital Markets. Hear his views on standardisation, partnerships and collaborations, data transfer and interoperability, and the impact of AI on the financial markets and the FinTech vendors that support it. He shares his experience of how smaller, nimble FinTech firms can help banks navigate internal hurdles around the adoption of new technology solutions, easing regulatory compliance headaches and the perseverance that is required to help clients achieve their goals.

In this episode our host Humpty Calderon speaks with Erik Ashdown of Covalent Covalent website: www.covalenthq.com Covalent (Twitter) X: @Covalent_HQ Erik Ashdown(Twitter) X: @eash0x Crypto Sapiens website: www.cryptosapiens.xyz Crypto Sapiens (Twitter) X: @cryptosapiens_     This conversation covers topics such as the background of Covalent, the future of data availability, the importance of accessibility in blockchain, the evolution of wallets, the future of applications on blockchain, DeFi as the end state, Covalent's role in the future, onboarding more chains to Covalent, the Ethereum Way Back Machine, and the value of historical data. The conversation explores the challenges of data integration and making sense of disconnected data in the blockchain space. It highlights the importance of storing and organizing data for long-term availability, especially for purposes like tax reporting. Covalent is working on addressing this issue by providing a solution that incentivizes data storage and makes it easy to extract data from multiple chains. The conversation also includes a call to action for developers to start using Covalent's data and provides information on grants and resources available. Additionally, the collaboration between Covalent and Mosaic in curating on-chain media and musical experiments is discussed.   Takeaways Covalent aims to provide long-term data availability and accessibility in the blockchain space. The future of applications on blockchain will involve social elements and the integration of AI. DeFi is seen as the end state of blockchain, but there is still a long way to go in terms of infrastructure and usability. Covalent's goal is to onboard more chains and provide accessible data to developers and applications. The Ethereum WayBack Machine refers to Covalent's ability to provide historical data on the Ethereum blockchain. Historical data has value for various purposes   Timestamps: 00:47  - Introductions and Background on Covalent 01:21 - Erik's Journey in Crypto 06:27 - The Future of Data Availability 11:51 - The Importance of Accessibility in Blockchain 13:07 - The Evolution of Wallets 15:50 - The Future of Applications on Blockchain 20:29 - DeFi as the End State 24:49 - Covalent's Role in the Future 28:38 - Onboarding More Chains to Covalent 33:24 - The Ethereum Way Back Machine 35:08 - The Value of Historical Data 36:07 - Data Integration and Making Sense of Disconnected Data 38:34 - Long-Term Data Availability 47:42 - Getting Started with Covalent's Data 44:08 - Call to Action for Developers 48:41 - Covalent and Mosaic Collaboration 50:15 - On-Chain Media and Musical Experiments

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to re-establish BTK inhibition.

In our latest episode of Web3 Unpacked, Rich Pasqua of @mvmtmedia / Arc, speaks with Kevin Callahan, CEO of Uniblock, a free platform that sits on top of all the best developer tools and provides a simple, unified API gateway to the world of Web3 technologies.UX and usability is something we're seeing on the consumer side clearly, but it's also equally, if not more important on the developer side because if developers can build stuff, developers are a leading indicator of what we will enjoy as consumers.- Kevin CallahanABOUT UniblockUniblock is a free platform that sits on top of all the best developer tools such as Alchemy, Covalent and QuickNode, in order to provide not only hundreds of APIs and smart contracts, but also useful features like load balancing, fallback, and API key management. On top of all these features Uniblock negotiates superior pricing with our partners, and passes these savings on to you in one simple monthly bill.LEARN MORE ABOUT Arc/MVMThttps://linktr.ee/mvmt.mediahttps://arctai.com#Web3 #web3developer #Alchemy #Covalent #QuickNode #rust #solidity #devtools #hardhat #ethers #openzeppelin #metamask Truffle #solana #vyper #chainstack #remix #etherspot #web3unpacked

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.Co-Chair and ModeratorNirav Shah, MD, MSFroedtert Hospital and the Medical College of WisconsinMilwaukee, WisconsinCo-Chair and PresenterDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MDOxford University HospitalsNHS Foundation TrustOxford, United Kingdom In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyPVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerNirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.Co-Chair/PlannerDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.Grant/Research Support from AstraZeneca and BeiGene.Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

OpenAI's large-scale language-generation tool ChatGPT may have been used to draft some content in this episode and some of the show notes of this episode. StudySquare Ltd has adapted the content, and the publication is attributed to StudySquare Ltd. This episode is a general guideline for information and not a specific tutorial for any specific syllabus; therefore, it should not be relied upon. StudySquare Ltd and any people involved in producing this podcast take no responsibility or liability for any potential errors or omissions regarding this podcast and make no guarantees of any completeness, accuracy, or usefulness of the information contained in this podcast, its structure or its show notes. The problems or questions in this episode might not appear in exam papers.The content in this episode might be more relevant to learners in the United Kingdom. Laws, educational standards, and exam requirements may vary significantly from one location to another. It's the listener's responsibility to confirm that the material complies with the requirements and regulations of their local educational system. If any content of this episode does not comply with your local regulations or laws, please discontinue listening and consult with your local educational authorities.Any references to experiments in this episode are for information purposes only and do not allow any listener to perform them without proper guidance or support. Experiments or practical work mentioned during this episode should not be attempted without appropriate supervision from a qualified teacher or professional. Additionally, the information provided in our podcast is not medical advice and should not be taken as such. If you require medical advice, please consult a healthcare professional. This episode is provided 'as is' without any representations or warranties, express or implied.This episode covers the following:• Covalent bonding• Ionic bonding• Metallic bonding• Covalent structures• Dot and cross diagrams• Page for this topic: https://studysquare.co.uk/test/Chemistry/Edexcel/A-level/Bonding?s=p• Trial lesson (terms and conditions apply): https://www.studysquare.co.uk/trial?s=p-/test/Chemistry/Edexcel/A-level/Bonding• Privacy policy of Spreaker (used to distribute this episode): https://www.spreaker.com/privacy

References JBC.2002. Volume 277, ISSUE 2, P1128-1138. Cancer Discov. 2022 Mar 1; 12(3): 856–871. Guerra lectures-lipid metabolic regulation Guerra lectures-pharmacodynamics and kinetics --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message

References Guerra general graduate biochemistry lectureImmunol Res. 2020 Feb;68(1):28-38. doi: 10.1007/s12026-020-09125-9. --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message

Activist, politician and author Stacey Abrams discusses her new thriller “Rogue Justice.” Then, prolific Atlanta artist Peter Ferrari details “Covalent,” his new exhibition at ABV Gallery. Plus, our series, “Speaking of Poetry,” shines a light on Atlanta poet Carlos Barboza.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this video, we dive deep into the world of Covalent, a cutting-edge blockchain data platform that's transforming the way we access and analyze blockchain data. Joining us is Ganesh Swami, the CEO of Covalent, who provides us with an in-depth overview of the platform, its key features, and its potential use cases. Through this interview, we explore how Covalent simplifies blockchain data for developers, investors, and enterprises, making it easier to build and deploy decentralized applications. Ganesh also highlights some of the challenges that the Covalent team has faced and how they have overcome them to create a powerful blockchain data platform. Whether you're a blockchain enthusiast, developer, or investor, this video will provide you with valuable insights into the world of Covalent and its potential to revolutionize the blockchain space. So, grab a cup of coffee and join us for this exciting conversation with Ganesh Swami, the CEO of Covalent.

References Nature Reviews Immunology volume 18, pages 617–634 (2018) Genes (Basel). 2021 Aug; 12(8): 1118. --- Send in a voice message: https://anchor.fm/dr-daniel-j-guerra/message Support this podcast: https://anchor.fm/dr-daniel-j-guerra/support

Ganesh Swami is the CEO and co-founder of Covalent - a Web3 data analytics company offering a unified API that brings visibility to billions of blockchain data points. His focus with Covalent is to provide the richest and most robust data infrastructure requiring no code and is easy to use – for the entire blockchain ecosystem. In this episode we discuss the following: Data analysis and trends within crypto industry (across NFTs, DEXs, wallets, more) Price movement and market trends Entrepreneurship and bringing Web3 products to the market  Transitioning from Web2 to Web3; mainstream adoption of Web3

cryptogaming.institute twitter.com/cryptogamingi

This program is recorded in my Discord group "NihonGO Japanese Language School", we offer group lessons for free, almost every day! Feel free to join the server and our lesson anytime ;) "NihonGO Japanese Language School" https://discord.gg/WEMKCAGhxA === #nihongopodcast #japanese #日本語 #giapponese #日文 #日语 #일본어 #ญี่ปุ่น #japonais #japonés #japonês #nihongo #hiragana #katakana #studyjapanese #learnjapanese #japanesephrases #japantrip #japantravel #jlpt #日本語能力試験 #kanji #japaneselanguage #japanesepodcast #にほんご #ひらがな #カタカナ #japan --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

On this episode of the DIVI Crypto Podcast our host Steve McGarry is joined by Ganesh Swami, CEO and Co-Founder of Covalent. Ganesh is a physicist by training who worked on Cancer medicine, but he dives into his crypto origin story. Steve asks about Covalent and what their mission is, and they talk about the fundamental problems with blockchains today. Ganesh discusses the use cases and the current status of Covalent. Steve asks about the token they offer, and what excites Ganesh about the industry today. Covalent is a technology company that is solving the huge infrastructure problems inhibiting blockchain adoption. Their solution bridges the entrenched world of centralized databases with the new world of distributed blockchain technologies. - Twitter @Covalent_HQ - https://twitter.com/Covalent_HQ - LinkedIn - https://www.linkedin.com/in/ganswami/ - Website - https://www.covalenthq.com/ – DIVI is creating the world's first closed-loop, vertically-integrated cryptocurrency ecosystem. Much like Apple's ecosystem is anchored by iCloud, the DIVI Project blockchain serves as the core of the DIVI network of technologies. Thanks to a keen understanding of the divide that separates the mainstream from the crypto world, the DIVI team is able to create solutions to the industry's biggest problem: adoption by non-technical users. DIVI's user-friendly, one-click solutions aim to bring blockchain-based payments into modernity with great UX. In this podcast, we will cover all aspects of cryptocurrency, hot topics, and technology as worldwide adoption grows.

In this episode of CRYPTO 101, brought to you by Nord VPN, we talk to Ganesh Swami of Covalent about how his "One Unified API" company acts as a bridge for blockchain systems working either together or complimentary of one another. Sponsored link: nordvpn.com/crypto101 – NordVPN Plan discount + Free Threat Protection + 1 additional month for free. Guest Links: https://twitter.com/gane5h?lang=en https://twitter.com/Covalent_HQ https://www.covalenthq.com/ Show Links: https://CRYPTO101podcast.com Patreon: www.patreon.com/user?u=8429526 Twitter: https://twitter.com/Crypto101Pod https://twitter.com/BrycePaul101 https://instagram.com/crypto_101 Facebook: https://www.facebook.com/groups/101Crypto https://www.facebook.com/CRYPTO101Podcast **THIS IS NOT FINANCIAL OR LEGAL ADVICE** © Copyright 2022 Boardwalk Flock, LLC All Rights Reserved ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬ Fog by DIZARO https://soundcloud.com/dizarofr Creative Commons — Attribution-NoDerivs 3.0 Unported — CC BY-ND 3.0 Free Download / Stream: http://bit.ly/Fog-DIZARO Music promoted by Audio Library https://youtu.be/lAfbjt_rmE8 ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬

Meet Abhishek, co-founder of Covalent, a platform that drives engagement and growth for communities, events, and cohort-based courses through member matching & introductions. Covalent makes curated matches between members based on relevance (background, industry, topics of interest, etc.) and creates personalized introductions at scale. Every month, Covalent makes thousands of introductions, creating meaningful connections for amazing people from around the globe. Website: https://covalent.live Abhishek's LN: https://www.linkedin.com/in/abhishek-bhargava/ Company Profile: www.wearegenz.org/database *Don't forget to like, follow, subscribe, rate, or review!*

In this episode of CRYPTO 101, brought to you by Nord VPN, we talk to Ganesh Swami of Covalent about how his "One Unified API" company acts as a bridge for blockchain systems working either together or complimentary of one another. Sponsored link: nordvpn.com/crypto101 – NordVPN Plan discount + Free Threat Protection + 1 additional month for free. Guest Links: https://twitter.com/gane5h?lang=en https://twitter.com/Covalent_HQ https://www.covalenthq.com/ Show Links: https://CRYPTO101podcast.com Patreon: www.patreon.com/user?u=8429526 Twitter: https://twitter.com/Crypto101Pod https://twitter.com/BrycePaul101 https://instagram.com/crypto_101 Facebook: https://www.facebook.com/groups/101Crypto https://www.facebook.com/CRYPTO101Podcast **THIS IS NOT FINANCIAL OR LEGAL ADVICE** © Copyright 2022 Boardwalk Flock, LLC All Rights Reserved ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬ Fog by DIZARO https://soundcloud.com/dizarofr Creative Commons — Attribution-NoDerivs 3.0 Unported — CC BY-ND 3.0 Free Download / Stream: http://bit.ly/Fog-DIZARO Music promoted by Audio Library https://youtu.be/lAfbjt_rmE8 ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Talks Tech: Leilani Ledingham, Product Marketing Manager - API at Covalent, gave a talk entitled Accessing Multi-Chain Data with One Unified API. Enjoy! Career Nav: This week we have a talk entitled What My Coding Bootcamp Didn't Teach Me with Jennifer Diaz, Junior Software Engineer at The Wanderlust Group. Conversations: Valerie Aguilar, Senior Software Engineer at Motive talks about her move to Silicon Valley, the career challenges that came with that move, her advice for finding the courage to speak, and her ongoing commitment to mental health.

Summer is officially here and so is travel. Something you might see or use out and about are single use utensils. Newlight Technologies is revolutionizing typically wasteful products and materials. Please welcome CEO and Co-Founder, Mark Herrema, on the Make Climate Cool Again Podcast. Mark has spent the last 15 years developing a revolutionary new biomaterial called AirCarbon. By feeding greenhouse gasses to microorganisms found in the ocean, Newlight is able to extract AirCarbon and use it to replace plastic, leather, acetate and other fibers. Naturally regenerative and carbon-negative, AirCarbon has been used to create Restore FoodWare, which is carried nationwide by Target and has been implemented into Shake Shack locations, and Covalent fashion. A few months ago, it was announced that the use of AirCarbon is going to be explored by Nike in an effort to reduce their carbon footprint further. Sustainability Help Desk Special Promotion for the first 10 that join: https://www.patreon.com/makeclimatecoolagain?fan_landing=true PRODUCTION TEAM: Music: Jake Huffman Artwork: Groove Street Editing: Ivy Moore --- Send in a voice message: https://anchor.fm/makeclimatecool/message

Ganesh Swami is a serial entrepreneur, adventurer, and speaker. He is currently the co-founder and CEO of Covalent – a venture-funded blockchain data analytics startup based out of Vancouver, BC. He has over a decade of experience with database technology and bringing new products to market. His current focus with Covalent is to solve the big problems inhibiting blockchain's mainstream adoption. He started his career in building protein simulation algorithms to solve cancer.In this conversation, we discuss:- Building protein simulation algorithms to solve cancer- How P2E games are becoming such a hot topic and what we found in our analysis- Why people need granular, historical data, and how accessible they are- How developers and analysts can use our Unified API for free, without coding- How Covalent help with TAX seasons- What is on-chain analysis, why do people need them- Granular, historical data, and how accessible they are- $25mil in funding to data verification space CovalentWebsite: covalenthq.com Twitter: @Covalent_HQDiscord: covalenthq.com/discordGanesh Swami Twitter: @gane5h LinkedIn: Ganesh Swami---------------------------------------------------------------------------------  This episode is brought to you by PrimeXBT.  PrimeXBT offers a robust trading system for both beginners and professional traders that demand highly reliable market data and performance. Traders of all experience levels can easily design and customize layouts and widgets to best fit their trading style. PrimeXBT is always offering innovative products and professional trading conditions to all customers.  PrimeXBT is running an exclusive promotion for listeners of the podcast. After making your first deposit, 50% of that first deposit will be credited to your account as a bonus that can be used as additional collateral to open positions.  Code: CRYPTONEWS50  This promotion is available for a month after activation. Click the link below:  PrimeXBT x CRYPTONEWS50

As part of the World of UX 2-year anniversary celebration, Darren engages in an extremely enriching, energetic, and enlightening dialogue with UX veterans D. Ben Woods (CEO of Covalent and COO of Onedrus) and Michelle Pakron (Head of UX at ChaiOne). Topics covered during these set include the UX job market, portfolios, churn, and the importance of UX professional empowerment. Check out this extended episode today!!! #ux#eq#podcasts#cxofmradio#cxofm#realuxtalk#worldofuxCheck out the new World of UX website at https://www.worldoux.com.Visit the UX Uncensored blog at https://uxuncensored.medium.com. 

In this episode, we talk to Ganesh Swami, co-founder of Covalent. Covalent provides a unified API that brings visibility to billions of blockchain data points. There are over 500 cryptocurrency projects using Covalent's API currently. We talk to Ganesh about Covalent's origins, technology, and its future.

In this conversation, we chat with Dan Heyman, Co-founder and CEO of Palm NFT Studio and Network. Dan is a blockchain industry leader with experience building and leading organisations through the design, development and implementation of enterprise-grade blockchain protocols. Prior to Palm, Dan was the co-founder and Program Director of PegaSys, focusing on the strategy and operations of the team. Prior to joining PegaSys and ConsenSys, he was co-founder and CEO of Stack AI, COO of the Demeter Entrepreneur Support Network and Project Manager at MIT's Poverty Action Lab. He has an M.B.A. from MIT Sloan and a B.A. in Mathematics and Economics from Columbia University. More specifically, we touch on Dan's fascinating journey from working with the poverty action lab to founding Palm, as well as, Dan's experience at MIT, ConsenSys's enterprise solutions, the philosophy behind Crypto Art, NFTs and their value to large media enterprises, setting up a creator-focussed DAO, some exciting upcoming collaborations with DC Comics, and so much more!

CME credits: 0.50 Valid until: 17-04-2023 Claim your CME credit at https://reachmd.com/programs/cme/non-covalent-btk-inhibitors-for-b-cell-malignancies-mclcll-setting-the-stage-for-future-use/13384/ During the past 10 years, BTK inhibitors are increasingly replacing chemotherapy-based regimens, especially in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Current clinical practice is continuous long-term administration of covalent, irreversible BTK inhibitors, which can be complicated by side effects or the development of drug resistance. Resistance mutations and intolerance contribute to therapy interruption or discontinuation and abrogate clinical benefits associated with continued covalent BTK inhibitor therapy, leading to subsequent care that is suboptimal due to a dearth of effective treatment options (as reflected in lower progression-free survival, overall survival, or response duration). Non-covalent, reversible BTK inhibitors do not bind to C481, therefore providing a potentially effective option to patients with B cell malignancies that have developed resistance to covalent BTK inhibitors. Preliminary clinical studies have suggested that non-covalent BTK inhibitors are effective and well-tolerated. This educational activity will assist hematology-oncology professionals develop management plans designed to overcome these challenges and offer patients the full benefit of BTK inhibitor therapy. We will discuss the clinical implications of BTK inhibitor selectivity profiles and safety differences; the integration of BTK inhibitors into the management of different B-cell cancer patient populations; and the proactive adaptation of treatment plans to …

CME credits: 0.50 Valid until: 17-04-2023 Claim your CME credit at https://reachmd.com/programs/cme/non-covalent-btk-inhibitors-for-b-cell-malignancies-mclcll-setting-the-stage-for-future-use/13384/ During the past 10 years, BTK inhibitors are increasingly replacing chemotherapy-based regimens, especially in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Current clinical practice is continuous long-term administration of covalent, irreversible BTK inhibitors, which can be complicated by side effects or the development of drug resistance. Resistance mutations and intolerance contribute to therapy interruption or discontinuation and abrogate clinical benefits associated with continued covalent BTK inhibitor therapy, leading to subsequent care that is suboptimal due to a dearth of effective treatment options (as reflected in lower progression-free survival, overall survival, or response duration). Non-covalent, reversible BTK inhibitors do not bind to C481, therefore providing a potentially effective option to patients with B cell malignancies that have developed resistance to covalent BTK inhibitors. Preliminary clinical studies have suggested that non-covalent BTK inhibitors are effective and well-tolerated. This educational activity will assist hematology-oncology professionals develop management plans designed to overcome these challenges and offer patients the full benefit of BTK inhibitor therapy. We will discuss the clinical implications of BTK inhibitor selectivity profiles and safety differences; the integration of BTK inhibitors into the management of different B-cell cancer patient populations; and the proactive adaptation of treatment plans to …

This week, Darren is joined by one of his former professors in the Kent State University program, D. Ben Woods, the Owner and UX Consultant with Covalent. Check out this extended session and the latest installment of the Talkin' Shop series as Ben shares his take on several factors associated with today's world of user experience, #ux#eq#podcasts#cxofmradio#cxofm#realuxtalk#worldofuxCheck out the new World of UX website at https://www.worldoux.com.Visit https://www.workwithcovalent.com for more info on Ben's company and how they can help with your organization's UX initiatives.

Tom shares with us some of his journey and how that led him to co-found Biomea Fusion. We discuss some of the science behind irreversible drugs and covalent bonding. Using their fusion system there is greater potential for high selectivity, deep inactivation of target, and a greater therapeutic window.https://biomeafusion.com/https://thebiotechiqpodcast.com/podcast/

Ganesh is the CEO of Covalent, which is a Blockchain company that started out at Launch Academy a few years ago. Ganesh and Covalent are on a mission to solve the data infrastructure problems preventing the blockchain industry from growing and becoming widely adopted. Some of their biggest milestones lately: a billion-dollar valuation and the recent launch of their DAO. Social Media: Twitter: @gane5h @Covalent_HQ Follow Launch Academy on Twitter, LinkedIn, and Instagram for more start-up content.

Covalent Modifications are changes made to a protein to accomplish a variety of tasks (activate, deactivate, etc). I discuss Small Post-translational Modifications, Zymogens, and Suicide Inhibitors.